AIMS/HYPOTHESIS: The small, highly conserved vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis. However, its effects in diabetes-associated atherosclerosis have not been assessed. METHODS: Endothelial cells were grown in normal- and high-glucose (5 and 25 mmol/l) media with and without UII (10⁻⁸ mol/l) and/or the UII receptor antagonist, SB-657510 (10⁻⁸ mol/l). Apoe knockout (KO) mice with or without streptozotocin-induced diabetes were treated with or without SB-657510 (30 mg kg⁻¹ day⁻¹; n = 20 per group) and followed for 20 weeks. Carotid endarterectomy specimens from diabetic and non-diabetic humans were also evaluated. RESULTS: In high (but not normal) glucose medium, UII significantly increased CCL2 (encodes macrophage chemoattractant protein 1 [MCP-1]) gene expression (human aortic endothelial cells) and increased monocyte adhesion (HUVECs). UII receptor antagonism in diabetic Apoe KO mice significantly attenuated diabetes-associated atherosclerosis and aortic staining for MCP-1, F4/80 (macrophage marker), cyclooxygenase-2, nitrotyrosine and UII. UII staining was significantly increased in carotid endarterectomies from diabetic compared with non-diabetic individuals, as was staining for MCP-1. CONCLUSIONS/ INTERPRETATION: This is the first report to demonstrate that UII is increased in diabetes-associated atherosclerosis in humans and rodents. Diabetes-associated plaque development was attenuated by UII receptor antagonism in the experimental setting. Thus UII may represent a novel therapeutic target in the treatment of diabetes-associated atherosclerosis.
AIMS/HYPOTHESIS: The small, highly conserved vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis. However, its effects in diabetes-associated atherosclerosis have not been assessed. METHODS: Endothelial cells were grown in normal- and high-glucose (5 and 25 mmol/l) media with and without UII (10⁻⁸ mol/l) and/or the UII receptor antagonist, SB-657510 (10⁻⁸ mol/l). Apoe knockout (KO) mice with or without streptozotocin-induced diabetes were treated with or without SB-657510 (30 mg kg⁻¹ day⁻¹; n = 20 per group) and followed for 20 weeks. Carotid endarterectomy specimens from diabetic and non-diabetichumans were also evaluated. RESULTS: In high (but not normal) glucose medium, UII significantly increased CCL2 (encodes macrophage chemoattractant protein 1 [MCP-1]) gene expression (human aortic endothelial cells) and increased monocyte adhesion (HUVECs). UII receptor antagonism in diabetic Apoe KO mice significantly attenuated diabetes-associated atherosclerosis and aortic staining for MCP-1, F4/80 (macrophage marker), cyclooxygenase-2, nitrotyrosine and UII. UII staining was significantly increased in carotid endarterectomies from diabetic compared with non-diabetic individuals, as was staining for MCP-1. CONCLUSIONS/ INTERPRETATION: This is the first report to demonstrate that UII is increased in diabetes-associated atherosclerosis in humans and rodents. Diabetes-associated plaque development was attenuated by UII receptor antagonism in the experimental setting. Thus UII may represent a novel therapeutic target in the treatment of diabetes-associated atherosclerosis.
Authors: F Cipollone; C Prontera; B Pini; M Marini; M Fazia; D De Cesare; A Iezzi; S Ucchino; G Boccoli; V Saba; F Chiarelli; F Cuccurullo; A Mezzetti Journal: Circulation Date: 2001-08-21 Impact factor: 29.690
Authors: Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak Journal: Br J Pharmacol Date: 2005-07 Impact factor: 8.739
Authors: P Cirillo; S De Rosa; M Pacileo; A Gargiulo; V Angri; I Fiorentino; N Prevete; G Petrillo; R De Palma; A Leonardi; A De Paulis; M Chiariello Journal: J Thromb Haemost Date: 2008-02-12 Impact factor: 5.824
Authors: Paul Lewis; Nada Stefanovic; Josefa Pete; Anna C Calkin; Sara Giunti; Vicki Thallas-Bonke; Karin A Jandeleit-Dahm; Terri J Allen; Ismail Kola; Mark E Cooper; Judy B de Haan Journal: Circulation Date: 2007-04-09 Impact factor: 29.690
Authors: D Pearson; J E Shively; B R Clark; I I Geschwind; M Barkley; R S Nishioka; H A Bern Journal: Proc Natl Acad Sci U S A Date: 1980-08 Impact factor: 11.205
Authors: Eoin P Brennan; Muthukumar Mohan; Aaron McClelland; Christos Tikellis; Mark Ziemann; Antony Kaspi; Stephen P Gray; Raelene Pickering; Sih Min Tan; Syed Tasadaque Ali-Shah; Patrick J Guiry; Assam El-Osta; Karin Jandeleit-Dahm; Mark E Cooper; Catherine Godson; Phillip Kantharidis Journal: J Am Soc Nephrol Date: 2018-02-28 Impact factor: 10.121
Authors: C Lecointre; L Desrues; J E Joubert; N Perzo; P-O Guichet; V Le Joncour; C Brulé; M Chabbert; R Leduc; L Prézeau; A Laquerrière; F Proust; P Gandolfo; F Morin; H Castel Journal: Oncogene Date: 2015-01-19 Impact factor: 9.867
Authors: Stephen P Gray; Jay C Jha; Kit Kennedy; Erik van Bommel; Phyllis Chew; Cedric Szyndralewiez; Rhian M Touyz; Harald H H W Schmidt; Mark E Cooper; Karin A M Jandeleit-Dahm Journal: Diabetologia Date: 2017-02-03 Impact factor: 10.122
Authors: Isabella Albanese; Stella S Daskalopoulou; Bin Yu; Zhipeng You; Jacques Genest; Alawi Alsheikh-Ali; Adel G Schwertani Journal: Front Pharmacol Date: 2016-06-07 Impact factor: 5.810